Abstract
PurposeThis study examined clinical and economic outcomes among patients with advanced hepatocellular carcinoma (HCC) treated with systemic agents by line of therapy.MethodsAdults with ≥ 2 medical claims for primary diagnosed HCC (from January 1, 2008, through September 30, 2015) and ≥ 1 claim for systemic HCC-related therapy were identified in the IBM MarketScan® Research Databases. Continuous enrollment was required 6 months before and 1 month after diagnosis. Patients were categorized into first- (1L) and second-line (2L) treatment cohorts; those receiving sorafenib as 1L were evaluated. Treatment patterns, healthcare resource utilization, costs, and survival during 1L and 2L therapy were measured. Survival was assessed for patients linked to the Social Security Administration Master Death File.Results1459 patients, 758 with death data, met the 1L cohort criteria; 163 patients, 87 with death data, later received 2L therapy. 77.1% had 1L sorafenib, alone or in combination. Median 1L treatment duration was 3.0 months; median survival time from start of 1L to death or censor was 6.8 months. There was no predominant 2L agent. Median 2L treatment duration was 3.0 months; median survival time from start of 2L was 9.3 months. Median total healthcare costs per patient per month were $13,297 for 1L (all), $13,471 for 1L (sorafenib), and $11,786 for 2L.ConclusionsFindings confirm high 1-year mortality for advanced HCC, suggesting a high cost burden. While no 2L therapy was available during this analysis, recently approved 2L agents have the potential to improve survival after sorafenib failure or intolerance.
Highlights
Hepatocellular carcinoma (HCC) is the most common primary liver cancer in the USA
Patients diagnosed with early stage HCC who are eligible for surgical resection or transplantation can achieve 5-year survival rates of over 60%; there has been considerable focus on identification and monitoring of the at-risk population [2, 4]
For most patients who are diagnosed later with unresectable advanced HCC [3], 1-year survival is less than 40% and approved treatment options are limited [5, 6]
Summary
Hepatocellular carcinoma (HCC) is the most common primary liver cancer in the USA. MI, USA between 1975 and 2005 and has continued to increase, reaching an incidence of 6.7 cases per 100,000 persons in 2012 [1,2,3,4]. Patients diagnosed with early stage HCC who are eligible for surgical resection or transplantation can achieve 5-year survival rates of over 60%; there has been considerable focus on identification and monitoring of the at-risk population [2, 4]. For most patients who are diagnosed later with unresectable advanced HCC (aHCC) [3], 1-year survival is less than 40% and approved treatment options are limited [5, 6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
